Research.Patient.info
KRAS p.G12C Mutant Advanced Solid Tumors research hub
2 indexed studies · 1 currently recruiting
- recruitingPhase I and Phase II (Integrated)- First administration to humans
A Phase 1/2, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of Sotorasib (AMG 510) Monotherapy in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation and Sotorasib (AMG 510) Combination Therapy in Subjects With Advanced NSCLC With KRAS p.G12C Mutation (CodeBreaK 100)
This study is testing a new medicine, Sotorasib, for people with advanced cancers that have a specific genetic change called KRAS p.G12C. Researchers want to see if it's safe and effective, both on its own and when combined with other treatments.
Spain · France · Belgium - active not recruitingPHASE1, PHASE2
A Phase 1/2, Study Evaluating the Safety, Tolerability, PK, and Efficacy of Sotorasib (AMG 510) in Subjects With Solid Tumors With a Specific KRAS Mutation (CodeBreaK 100)
This study is testing a new medicine called sotorasib for people with specific advanced cancers carrying a KRAS p.G12C gene change. Researchers want to see if it's safe, how much to give, and if it helps shrink tumours. It's an early-stage trial looking for better cancer treatments.
United States · Australia · Austria